Back to search

Article

Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphoma

2025-04-23

Abstract excerpt

Diffuse large B-cell lymphoma (DLBCL) refers to an aggressive lymphoma that arises from germinal center (GC) B-cells, which differentiate into plasma cells (PC) to produce high affinity antibodies. 40% of DLBCL patients relapse or are refractory to the conventional immunochemotherapy treatment, usually with fatal consequences. Therefore, there is an unmet critical need to find more targeted therapies for DLBCL. DL...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
0e3e04ec-9388-59ef-8eeb-ff84df9aa26a
DOI
10.1101/2025.04.21.648509
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Enhanced efficacy of a specific HDAC3 inhibitor in combination with 5-Azacitidine against diffuse large B-cell lymphomaDOI 10.1101/2025.04.21.648509
Targeting HDACs for diffuse large B-cell lymphoma therapySemantic proximity
The epigenetic basis of diffuse large B-cell lymphoma.Semantic proximity
Methylation alterations and advance of treatment in lymphomaSemantic proximity
Epigenetic Symphony in Diffuse Large B-Cell Lymphoma: Orchestrating the Tumor MicroenvironmentSemantic proximity
Comprehensive analysis of HDAC7 expression and its prognostic value in diffuse large B cell lymphomaSemantic proximity
A Promising Future for Precision Epigenetic Therapy for Follicular and Diffuse Large B-Cell Lymphoma?Semantic proximity
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCLSemantic proximity
Molecular Pathogenesis of Non-Hodgkin's Lymphoma: the Role of Bcl-6Semantic proximity
Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.Semantic proximity
Selective inhibition of HDAC3 targets synthetic vulnerabilities and activates immune surveillance in lymphomaSemantic proximity
Epigenetic Mechanisms of Therapy Resistance in Diffuse Large B Cell Lymphoma (DLBCL).Semantic proximity
Dual targeting of aberrant DNA and histone methylation synergistically suppresses tumor cell growth in ATLSemantic proximity
Select a neighboring publication to make it the new centre.